We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Orgenesis Inc (ORGS) USD0.0001

Sell:$0.80 Buy:$0.82 Change: $0.12 (12.38%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$0.80
Buy:$0.82
Change: $0.12 (12.38%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$0.80
Buy:$0.82
Change: $0.12 (12.38%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Contact details

Address:
20271 Goldenrod Lane
GERMANTOWN
20876
United States
Telephone:
+1 (480) 6596404
Website:
https://www.orgenesis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ORGS
ISIN:
US68619K2042
Market cap:
$46.88 million
Shares in issue:
46.93 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Vered Caplan
    Chairperson of the Board of Directors, Chief Executive Officer
  • Victor Miller
    Chief Financial Officer, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.